TY - JOUR
T1 - Free-breathing, Contrast Agent–free Whole-Heart MTC-BOOST Imaging
T2 - Single-Center Validation Study in Adult Congenital Heart Disease
AU - Fotaki, Anastasia
AU - Pushparajah, Kuberan
AU - Hajhosseiny, Reza
AU - Schneider, Alina
AU - Alam, Harith
AU - Ferreira, Joana
AU - Neji, Radhouene
AU - Kunze, Karl P.
AU - Frigiola, Alessandra
AU - Botnar, René M.
AU - Prieto, Claudia
N1 - Funding Information:
Supported by the British Heart Foundation (grant nos. PG/18/59/33955, EPSRC EP/P001009, EP/P032311/1, EP/P007619), Wellcome EPSRC Centre for Medical Engineering (grant no. NS/A000049/1), Millennium Institute for Intelligent Healthcare Engineering (grant no. ICN2021_004), and the Department of Health via the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre award to Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Publisher Copyright:
© 2023, Radiological Society of North America Inc.. All rights reserved.
PY - 2023/2
Y1 - 2023/2
N2 - Purpose: To assess the clinical performance of the three-dimensional, free-breathing, Magnetization Transfer Contrast Bright-and-black blOOd phase-SensiTive (MTC-BOOST) sequence in adult congenital heart disease (ACHD). Materials and Methods: In this prospective study, participants with ACHD undergoing cardiac MRI between July 2020 and March 2021 were scanned with the clinical T2-prepared balanced steady-state free precession sequence and proposed MTC-BOOST sequence. Four cardiologists scored their diagnostic confidence on a four-point Likert scale for sequential segmental analysis on images acquired with each sequence. Scan times and diagnostic confidence were compared using the Mann-Whitney test. Coaxial vascular dimensions at three anatomic landmarks were measured, and agreement between the research sequence and the corresponding clinical sequence was assessed with Bland-Altman analysis. Results: The study included 120 participants (mean age, 33 years ± 13 [SD]; 65 men). The mean acquisition time of the MTC-BOOST sequence was significantly lower compared with that of the conventional clinical sequence (9 minutes ± 2 vs 14 minutes ± 5; P < .001). Diagnostic confidence was higher for the MTC-BOOST sequence compared with the clinical sequence (mean, 3.9 ± 0.3 vs 3.4 ± 0.7; P < .001). Narrow limits of agreement and mean bias less than 0.08 cm were found between the research and clinical vascular measurements. Conclusion: The MTC-BOOST sequence provided efficient, high-quality, and contrast agent–free three-dimensional whole-heart imaging in ACHD, with shorter, more predictable acquisition time and improved diagnostic confidence compared with the reference standard clinical sequence.
AB - Purpose: To assess the clinical performance of the three-dimensional, free-breathing, Magnetization Transfer Contrast Bright-and-black blOOd phase-SensiTive (MTC-BOOST) sequence in adult congenital heart disease (ACHD). Materials and Methods: In this prospective study, participants with ACHD undergoing cardiac MRI between July 2020 and March 2021 were scanned with the clinical T2-prepared balanced steady-state free precession sequence and proposed MTC-BOOST sequence. Four cardiologists scored their diagnostic confidence on a four-point Likert scale for sequential segmental analysis on images acquired with each sequence. Scan times and diagnostic confidence were compared using the Mann-Whitney test. Coaxial vascular dimensions at three anatomic landmarks were measured, and agreement between the research sequence and the corresponding clinical sequence was assessed with Bland-Altman analysis. Results: The study included 120 participants (mean age, 33 years ± 13 [SD]; 65 men). The mean acquisition time of the MTC-BOOST sequence was significantly lower compared with that of the conventional clinical sequence (9 minutes ± 2 vs 14 minutes ± 5; P < .001). Diagnostic confidence was higher for the MTC-BOOST sequence compared with the clinical sequence (mean, 3.9 ± 0.3 vs 3.4 ± 0.7; P < .001). Narrow limits of agreement and mean bias less than 0.08 cm were found between the research and clinical vascular measurements. Conclusion: The MTC-BOOST sequence provided efficient, high-quality, and contrast agent–free three-dimensional whole-heart imaging in ACHD, with shorter, more predictable acquisition time and improved diagnostic confidence compared with the reference standard clinical sequence.
KW - Cardiac
KW - MR Angiography
UR - https://www.scopus.com/pages/publications/85149329373
U2 - 10.1148/ryct.220146
DO - 10.1148/ryct.220146
M3 - Article
AN - SCOPUS:85149329373
SN - 2638-6135
VL - 5
JO - Radiology: Cardiothoracic Imaging
JF - Radiology: Cardiothoracic Imaging
IS - 1
M1 - e220146
ER -
SDG 3 Good Health and Well-being